comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 16:35:20 - browse：81

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Solve the antibiotic resistance crisis with preventive drugs

hotspot

WSS

Why health workers in Gaza are injured or die at high rates

Impact of Dobbs ruling felt at reproductive medicine meeting

Medical devices makers are asking for forgiveness, not permission

Medicare reduced heart disease by changing how it pays doctors

Texas board proposes rules on abortion law emergency exemption

FDA gives detailed accounting of AI

focus

comprehensive

leisure time

Walensky prepares to leave CDC — and Congress — behind

STAT Summit: GSK CEO on pharma giant's new direction

The cancer drug shortage isn’t new — and neither are the solutions

Diabetes management: Digital health tools fall short, study says

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

CRISPR technology availability, affordability needs to be expanded

Trump demands the U.S. pay no more for drugs than other countries … again

2023 STAT Wunderkinds: get to know the winners

ChatGPT in medicine: STAT answers readers' burning questions

Mirador, a new biotech startup, launches with $400 million

focus

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

FDA struggles to regulate food additives, sometimes for decades

Texas board proposes rules on abortion law emergency exemption

Texas board proposes rules on abortion law emergency exemption

First Opinion Podcast: Long Covid needs a new approach

Mirador, a new biotech startup, launches with $400 million

Wikipedia

knowledge

hotspot

focus